| 6.38 0.02 (0.31%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.73 | 1-year : | 9.03 |
| Resists | First : | 6.61 | Second : | 7.73 |
| Pivot price | 5.4 |
|||
| Supports | First : | 5 | Second : | 4 |
| MAs | MA(5) : | 6.1 |
MA(20) : | 5.35 |
| MA(100) : | 3.84 |
MA(250) : | 2.36 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 90.1 |
D(3) : | 87.4 |
| RSI | RSI(14): 69.6 |
|||
| 52-week | High : | 6.61 | Low : | 0.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ZURA ] has closed below upper band by 10.4%. Bollinger Bands are 81.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.58 - 6.6 | 6.6 - 6.63 |
| Low: | 5.89 - 5.92 | 5.92 - 5.95 |
| Close: | 6.33 - 6.38 | 6.38 - 6.42 |
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Fri, 23 Jan 2026
CEO shake-up at Zura Bio (NASDAQ: ZURA) with new director added - Stock Titan
Wed, 21 Jan 2026
Zura Bio appoints Sandeep Kulkarni as new CEO - Investing.com
Mon, 12 Jan 2026
Zura Bio Updates Outlook and Clinical Development Plans - TipRanks
Mon, 12 Jan 2026
Zura Bio Ltd Announces Corporate and Clinical Updates for 2026 - TradingView
Mon, 12 Jan 2026
Zura Bio expands HS trial, delays data readout to fourth quarter 2026 - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 24.4 (%) |
| Held by Institutions | 67.8 (%) |
| Shares Short | 2,850 (K) |
| Shares Short P.Month | 2,540 (K) |
| EPS | -0.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.65 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.3 % |
| Return on Equity (ttm) | -45.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -9.82 |
| PEG Ratio | 0 |
| Price to Book value | 3.84 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|